Kromasil HILIC-D
Kromasil HILIC-D is designed for the best selectivity of polar compounds.
Kromasil HILIC-D is designed for the best selectivity of polar compounds. Kromasil HILIC-D offers a column that is 100% MS compatible. The phase is low bleed and the solvents used when running your HPLC in HILIC mode are optimal for MS. Therefore the sensitivity can be 100 times better when using Kromasil HILIC-D over traditional RP columns.
Traditionally, polar compounds like organic acids, nucleobases, and water soluble vitamins have been a challenge to separate on a standard reversed phase column like C18. Kromasil HILIC-D offers a phase that has true orthogonal selectivity when compared to a C18 column, normally giving an opposite elution order. The diol derivatized Kromasil HILIC-D provides excellent reproducibility when compared to HILIC columns based on standard bare silica.
When purifying polar compounds, Kromasil HILIC-D can be scaled up, offering the same great performance as in analytical scale. Take advantage of the generous surface area which can provide high loading capacity.
To learn more and for a time limited special offer, contact us or visit our website.
Contact details
kromasil@akzonobel.comwww.kromasil.com/hilic
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
